Key Highlights

  • Vivani Medical (NASDAQ: VANI) will convert its subsidiary Cortigent into 12,500,000 shares of ClearOne common stock upon merger completion.
  • ClearOne plans to raise between $10,000,000 and $15,000,000 via a Form S-1 registration, issuing up to 5,000,000 units with warrants.
  • The deal includes a breakup fee capped at $250,000, payable under specified termination conditions.
  • ClearOne shareholders holding at least 50.1% of common stock have agreed to vote in favor of the merger.

Vivani Medical (NASDAQ: VANI) has entered a definitive merger agreement with ClearOne, marking a strategic move to combine its subsidiary Cortigent with the Nasdaq-listed company. The transaction positions Vivani to expand its footprint in the healthcare sector while securing a significant equity stake in the combined entity.

Merger Structure Unveiled

Under the terms of the agreement finalized July 1, 2026, Cortigent will merge with ClearOne’s subsidiary, MergerSub, becoming a wholly owned unit of ClearOne. The deal is structured as an all-stock transaction, with Vivani set to receive 12,500,000 shares of ClearOne common stock in exchange for its Cortigent equity.

Financing Conditions

The financing aims to secure between $10,000,000 and $15,000,000 through the sale of 2,500,000 to 5,000,000 units. Each unit will include one share of ClearOne common stock and a warrant exercisable at $10.00 per share for six months.

Shareholder and Regulatory Hurdles

The merger’s completion hinges on multiple conditions, including approval from both companies’ shareholders and compliance with regulatory requirements. ClearOne must maintain its Nasdaq listing, and the newly issued shares must receive exchange approval. A majority of ClearOne shareholders, representing at least 50.1% of common stock, have already agreed to support the transaction.

Governance and Lock-Up Terms

Post-merger, the combined company’s board will consist of five directors, with Vivani designating four members, including the chairperson. Vivani has also agreed to customary lock-up restrictions on its newly acquired shares, though specific terms remain subject to mutual agreement with ClearOne.

Breakup Fee and Termination Clauses

The merger agreement includes a breakup fee provision, allowing either party to terminate the deal under specified circumstances. The fee is set at 125% of verifiable third-party expenses, capped at $250,000. The agreement also permits termination if the merger fails to close by December 28, 2026, absent an extension.

Strategic Implications for Vivani

The transaction aligns with Vivani’s focus on advancing its semaglutide implant technology, which has drawn interest from major pharmaceutical players. While the merger does not directly involve its partnership with Novo Nordisk, it provides Vivani with additional capital and operational flexibility to support its long-term pipeline.

Next Steps for Investors

The merger remains subject to customary closing conditions, including financing completion and shareholder votes.

FAQs

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.